Prudential PLC Sells 32,218 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Prudential PLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 319,162 shares of the biopharmaceutical company's stock after selling 32,218 shares during the quarter. Prudential PLC's holdings in Gilead Sciences were worth $21,898,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of GILD. International Assets Investment Management LLC acquired a new position in shares of Gilead Sciences during the fourth quarter valued at $1,649,000. Gilbert & Cook Inc. raised its stake in shares of Gilead Sciences by 5.3% during the fourth quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company's stock valued at $550,000 after purchasing an additional 344 shares in the last quarter. Aveo Capital Partners LLC raised its stake in shares of Gilead Sciences by 8.6% during the fourth quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company's stock valued at $443,000 after purchasing an additional 435 shares in the last quarter. Principal Securities Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at about $561,000. Finally, Cary Street Partners Investment Advisory LLC raised its stake in shares of Gilead Sciences by 47.2% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 6,313 shares of the biopharmaceutical company's stock valued at $511,000 after purchasing an additional 2,024 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent analyst reports. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research note on Friday, August 9th. Truist Financial lifted their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a "hold" rating in a research note on Thursday, August 15th. Robert W. Baird restated a "neutral" rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Cantor Fitzgerald restated a "neutral" rating and set a $70.00 price objective on shares of Gilead Sciences in a research note on Monday. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Twelve investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $81.25.

Gilead Sciences Trading Up 0.6 %

NASDAQ GILD traded up $0.45 on Monday, hitting $79.17. 5,570,112 shares of the company were exchanged, compared to its average volume of 7,154,367. The company's 50 day moving average price is $74.06 and its 200-day moving average price is $70.55. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a market capitalization of $98.57 billion, a P/E ratio of 220.97, a price-to-earnings-growth ratio of 2.73 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. The firm had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.89%. Gilead Sciences's dividend payout ratio (DPR) is presently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.